Skip to main content
Equibles
QNRX logo

QNRX · Quoin Pharmaceuticals, Ltd.

Track QNRX — free

Use QNRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about QNRX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$5.09 -0.96 (-15.87%) At close · Aug 14
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based upon the Company's current business plans and cash, cash equivalents, and investments on hand, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date of the filing of this Quarterly Report on Form 10-Q.”
View the 10-Q filed Aug 14, 2026
Market Cap
$357.80M
Shares
70.29M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.09 Open$5.00 Day$4.55–5.30 52W close$3.25–22.30 Avg vol 30d23K Short int116K · 0.2% float · 10.7d Short vol20% Last earningsMay 7, 2026 DataApr 2025–Aug 2026 Filing10-Q · Aug 14

Raw chart and full-history price indicators begin at the captured split on Apr 9, 2025; bars on opposite sides are not compared.

Up next

Next earnings call
Sep 9, 2026 Est · unconfirmed · in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −39%
below
Price vs 50-day avg +12%
above
RSI (14) 55
neutral
MACD trend Positive
52-week position 10%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +20%
trailing
6-month return −38%
trailing
YTD return −65%
this year
Relative strength −52%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $5 › 200d $8 — 200d above 50d
Institutional flow Distributing
-10% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.16% of float · ▼ -25.9% MoM · 10.7 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
19 holders — mid 3-yr range
Squeeze score 52
elevated · 0–100
Fundamentals
Excellent
EPS growth +99%
Y/Y
Balance sheet $3.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 194%
annualized · 1-yr
Max drawdown −85%
past year
ATR 9.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−39% Bearish
Price vs 50-day avg
+12% Bullish
RSI (14)
55 Neutral
MACD trend
Positive Bullish
52-week position
10% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $5 › 200d $8 — 200d above 50d
Institutional flow Distributing
-10% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.16% of float · ▼ -25.9% MoM · 10.7 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
19 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $5 · 10% Range high $22
vs 200-day avg -39% vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
QNRX
Quoin Pharmaceuticals, Ltd.
this stock
$357.80M -64.7% — — 0.2%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
19
% held
2.7%
Net QoQ
+680.7K sh
Top holder
Stonepine Capital Managem…
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Falling
Shares short
115.8K
Days to cover
10.7d
Change
-40.5K sh
View
Short Volume
Short vol %
20%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
100
Value
$467
As of
Jul 10, 2026
View
Off-Exchange
Off-exchange %
45.9%
Week of
Jul 6, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-15.8M
EPS diluted
$-52.50
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 14, 2026
This year
11
View
Proposed Sales
Value
$218
Shares
297
Filed
Jun 7, 2024
View
Exempt Offerings
Offering
$105.3M
Filed
Oct 23, 2025
View
Earnings & Events
Earnings Calls
Last call
May 7, 2026
View

Performance

Raw-price comparisons begin at the captured split on Apr 9, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
QNRX +6.3% +20.1% -37.9% +14.4% -64.7%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY +5.9% +15.6% -51.6% +10.5% -78.6%
Key facts CIK 1671502 CUSIP 74907L409 13F (30d) 18 filings 18 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)